Bio-Bridge Science Signs an Equity Sale and Purchase Agreement with Xinheng Baide Biotechnology Co. Ltd.
02 May 2008 - 12:16AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company
engaged in the commercial development of vaccines for the
prevention and treatment of human infectious diseases announced
today that its wholly-owned subsidiary, Bio-Bridge Science (HK)
Co., Ltd. has entered into a sale and purchase agreement (the
"Agreement") with Xinheng Baide Biotechnology Co. Ltd. (the
�Seller� or �Xinheng Baide�), a serum manufacturing company
organized under the laws of the PRC, pursuant to which BGES has
agreed to purchase newly issued shares of Seller. After the equity
issuance, BGES shall control 51% of the outstanding capital stock
of the Seller for a total cash purchase price of RMB 6 million
(approximately US$ 865,000). The source of the cash to be used for
subscribing to the new shares issued by the Seller will be from
working capital of BGES. Xinheng Baide, located in the city of
Huhhot in Inner Mongolia of the People�s Republic of China,
manufactures and distributes bovine serum and other related
products primarily in China. Bovine serum is used in vaccine
production as well as scientific research. The sale and purchase
agreement and related documents are subject to Chinese governmental
approval. BGES expects to close the deal at the end of May 2008.
Dr. Liang Qiao, Chairman and CEO of Bio-Bridge said, �We are happy
to see the execution of the sale and purchase agreement between
Xinheng Baide and Bio-Bridge. I expect Xinheng Baide to grow
significantly in the future from the synergies of both parties as
well as the expected increase in the demand for serum in China.
Xinheng Baide will fit into our strategic plan by providing a
potential steady, while growing, source of revenues to us, as well
as providing a new distribution channel for our products. I believe
the cooperation will be beneficial for both parties.� This press
release contains forward-looking statements. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying
assumptions and other statements that are other than statements of
historical facts. These statements are subject to uncertainties and
risks including, but not limited to, product and service demand and
acceptance, changes in technology, economic conditions, the impact
of competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to the Company's SEC filings for additional
information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bio Bridge Science Inc (CE) (OTCMarkets): 0 recent articles
More Bio-Bridge Science, Inc. News Articles